See more : Flexiroam Limited (FRX.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Valeo Pharma Inc. (VPHIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Valeo Pharma Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Pick n Pay Stores Limited (PIK.JO) Income Statement Analysis – Financial Results
- Sprout Social, Inc. (SPT) Income Statement Analysis – Financial Results
- Bharat Petroleum Corporation Limited (BPCL.NS) Income Statement Analysis – Financial Results
- Aurora Solar Technologies Inc. (AACTF) Income Statement Analysis – Financial Results
- ASLAN Pharmaceuticals Limited (ASLN) Income Statement Analysis – Financial Results
Valeo Pharma Inc. (VPHIF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.valeopharma.com
About Valeo Pharma Inc.
Valeo Pharma Inc., a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceutical products with primary focus on respiratory, speciality, and hospital generic products in Canada. Its product portfolio includes Enerzair Breezhaler, an LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, an LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, Idiopathic Parkinson's Disease (PD) as an add-on for patients on stable dose of Levodopa alone or in combination with other drugs; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma. In addition, it offers Hesperco, bioflavonoid antioxidant used for immune support; Ametop, for skin Anesthesia prior to venepuncture or venous cannulation; Benztropine, an VPI-Anticholinergic agent used for the treatment of PD; Ethacrynate Sodium, a loop diuretic for high blood pressure and associated swelling; and Amikacin, an injectable antibiotic. The company was incorporated in 2003 and is headquartered in Kirkland, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 53.91M | 27.75M | 13.56M | 7.47M | 6.58M | 4.38M | 1.28M | 985.71K |
| Cost of Revenue | 40.83M | 21.46M | 9.60M | 6.09M | 5.18M | 3.55M | 747.09K | 2.35M |
| Gross Profit | 13.08M | 6.28M | 3.96M | 1.38M | 1.40M | 832.97K | 530.40K | -1.37M |
| Gross Profit Ratio | 24.26% | 22.64% | 29.17% | 18.49% | 21.30% | 19.01% | 41.52% | -138.68% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 126.26K | 0.00 |
| General & Administrative | 22.56M | 18.81M | 13.31M | 3.32M | 3.04M | 2.98M | 2.84M | 1.10M |
| Selling & Marketing | 6.59M | 6.09M | 2.89M | 2.12M | 2.01M | 236.53K | 133.75K | 72.75K |
| SG&A | 29.15M | 24.90M | 16.19M | 5.45M | 5.05M | 3.22M | 2.98M | 1.01M |
| Other Expenses | 1.15M | 0.00 | 123.00K | 198.00K | 253.00K | 147.04K | 50.77K | 0.00 |
| Operating Expenses | 30.31M | 25.39M | 16.65M | 5.68M | 5.14M | 3.26M | 3.14M | 1.01M |
| Cost & Expenses | 71.14M | 46.86M | 26.25M | 11.77M | 10.31M | 6.81M | 3.89M | 3.36M |
| Interest Income | 3.72M | 173.00K | 1.00K | 1.00K | 0.00 | 816.00 | 368.00 | 114.17K |
| Interest Expense | 13.79M | 6.46M | 1.36M | 598.00K | 110.00K | 173.85K | 102.42K | 0.00 |
| Depreciation & Amortization | 2.63M | 1.42M | 743.00K | 424.00K | 135.00K | 44.47K | 40.12K | 38.56K |
| EBITDA | -11.39M | -17.56M | -11.86M | -3.74M | -3.41M | -2.33M | -2.55M | -2.34M |
| EBITDA Ratio | -21.13% | -63.28% | -87.47% | -49.44% | -51.85% | -53.13% | -199.81% | -237.24% |
| Operating Income | -17.23M | -19.60M | -12.94M | -4.12M | -3.55M | -2.37M | -2.59M | -2.38M |
| Operating Income Ratio | -31.96% | -70.66% | -95.45% | -55.11% | -53.90% | -54.15% | -202.95% | -241.15% |
| Total Other Income/Expenses | -10.58M | -7.32M | -1.42M | -644.00K | 122.00K | 28.00K | -1.86M | 460.53K |
| Income Before Tax | -27.81M | -26.92M | -14.23M | -4.76M | -3.62M | -2.40M | -4.50M | -1.92M |
| Income Before Tax Ratio | -51.58% | -97.03% | -104.99% | -63.73% | -54.96% | -54.78% | -352.25% | -194.43% |
| Income Tax Expense | 0.00 | -1.17M | 1.48M | 796.00K | 326.00K | 36.72K | -881.21K | -640.00K |
| Net Income | -27.81M | -25.75M | -14.23M | -4.76M | -3.62M | -2.44M | -3.62M | -1.28M |
| Net Income Ratio | -51.58% | -92.80% | -104.99% | -63.73% | -54.96% | -55.62% | -283.27% | -129.50% |
| EPS | -0.32 | -0.32 | -0.20 | -0.08 | -0.07 | -0.05 | -0.07 | -0.03 |
| EPS Diluted | -0.32 | -0.32 | -0.20 | -0.08 | -0.07 | -0.05 | -0.07 | -0.03 |
| Weighted Avg Shares Out | 86.12M | 80.86M | 69.93M | 57.91M | 49.59M | 48.47M | 48.47M | 44.90M |
| Weighted Avg Shares Out (Dil) | 86.12M | 80.86M | 69.93M | 57.91M | 49.59M | 48.47M | 48.47M | 44.90M |
Valeo Pharma enters commercialization and supply agreement with Novartis Canada for two ophthalmic therapies
Valeo Pharma posts 80% increase in 2Q revenue as lead products report strong growth
Valeo Pharma posts 128% increase in revenue in first quarter boosted by its three lead products
Valeo Pharma secures public reimbursement for Redesca and Redesca HP in British Columbia
Valeo Pharma reports record financial results for the fourth quarter and year-ended October 31, 2021
Valeo Pharma announces another major milestone for its two innovative asthma therapies
Valeo Pharma says its Hesperco immune support product is now available at select Loblaws stores across Canada
Valeo Pharma rapidly advancing in bid to become leading Canada-focused specialty pharma group
Valeo Pharma reveals a major milestone for its two innovative asthma therapies with reimbursements approved
Valeo Pharma increases size of previously announced bought deal private placement of convertible unsecured debentures to $15M
Source: https://incomestatements.info
Category: Stock Reports